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ABSTRACT 
Atopic dermatitis (AD) is an often severely itching, chronic, inflammatory skin 
disorder and may worsen due to stress and anxiety. Tachykinins have been suggested to 
influence the level of inflammation as well as being involved in pruritus, stress and 
anxiety.  
   The aim of the study was to investigate the role of tachykinins, including substance P 
and neurokinin (NK) A, in the pathogenesis of AD, pruritus and worsening during 
stress.  
   Initially an animal model was used to investigate innervation, substance P and the 
neurokinin (NK)-1 receptor (R) in relation to eczema and stress using an 
immunohistochemistry method. Chronic mild stress seemed to decrease innervation in 
eczematous skin lesions and we recorded a decrease in substance P positive fibres in 
stressed eczematous skin compared to in stressed control. In addition, a tendency of 
increased levels of NK-1R m-RNA in skin of stressed compared to non-stressed 
eczematous mice was apparent using PCR. A decrease of substance P 
immunoreactivity was detected in the medial hippocampus of the brain in stressed 
compared to in non-stressed eczematous mice. 
   Tachykinin expression was then examined in the skin of AD patients, and possible 
correlations to clinical and psychodemographic parameters were investigated. The 
numbers of substance P- and NKA positive nerve fibres and also of NKA positive 
dermal cells were increased in lesional compared to non-lesional skin. In addition, there 
was a correlation between the NK1-R positive cells, and the level of acanthosis and 
inflammation, in the lesional skin. There was also a correlation between the depression 
score and the number of the NK-1R positive cells in lesional as well as in non-lesional 
skin.  
   Finally, the effect of an NK-1R antagonist, aprepitant, was evaluated in adult patients 
with moderate-severe AD, compared to a standard topical treatment in an open 
randomized trial. In both the treatment group and the control group significant 
improvement was evident both regarding extent of disease and pruritus. However, there 
was not any significant additional improvement for any of these parameters in the 
aprepitant-treated patients compared to controls.  
   In conclusion, tachykinins seem to have a role in the pathogenesis and stress-
worsening of AD. However, this role seems to be complex and further investigations 
are needed to fully understand these connections.  
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1 BACKGROUND 
 
1.1 ATOPIC DERMATITIS – CLINICAL ASPECTS 
Atopic dermatitis (AD) is a common chronic inflammatory skin disease. The disease 
often appears in early childhood. It´s incidence has increased during past decades in 
industrialized countries. A lot of data concerning AD prevalence and trends has been 
drawn from the International Study of Asthma and Allergies in Childhood (ISAAC) 
(1). This study revealed that over 20% of children are affected by AD in some 
countries, but that the prevalence varies greatly throughout the world. The prevalence 
in the adult population is usually estimated to be 2-3%, but it is probably higher in 
industrialized countries. Studies have reported a prevalence varying between 0.3–
14.3% (2-5), indicating that this skin disease truly is also a problem in adults. 
   AD is characterized by eczematous lesions that in infants tend to localise to 
extremities and cheeks, while in elder children the eczema is often evident in the 
flexures of arms, legs and sometimes in the gluteal region. In adults the lesions often 
are located to neck, flexures, hands and face.  
   The histological features of acute AD include epidermal intercellular oedema and 
dermal perivascular infiltrates of inflammatory cells including lymphocytes, dendritic 
cells and a few eosinophils. During the chronic phase the lesional skin exhibits a 
thickened epidermis with a hypertrophied upper layer. The eczematous lesions are 
often characterized by a severe pruritus and this often affects the night sleep and quality 
of life. Psychological stress is known to be a factor that could trigger and worsen the 
eczema, and an exacerbation of the eczema is also in itself a stressor for the patient, 
often resulting in impaired quality of life and sleep disturbances. Chronic mild stress is 
a stress form that describes the everyday stressors and seems to be relevant from a 
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patient perspective. Chronic mild stress is connected to and not always easy to 
differentiate from anxiety and depression.  
   Typically the AD is associated with asthma and allergies, as a part in the atopic 
march or atopic triad (including AD, food allergy, allergic rhinitis, and asthma), and 
then often combined with high immunoglobulin (Ig)-E levels. One suggestion has been 
to distinguish “true” AD (extrinsic form) from non-IgE associated dermatitis (non-
atopic dermatitis, intrinsic form)(6). However, the development of IgE-antibodies, 
sensitisation and in some patients development of autoimmunity, has been suggested to 
be part of the development in different stages of AD. The other clinical characteristics 
of dry skin are also present in both types. Bieber (7) suggests that the development of 
AD has three phases; the initial non-atopic form in infancy when sensitization has not 
yet occurred, the second phase when sensitization to food or environmental allergens 
(in 60-80%) of patients takes place (transition to true AD) and lastly the development 
of autoantibodies in some patients as a result of skin damage due to scratching and 
inflammation. Thereby the division into two types of eczema has not yet become 
standard clinical practice.  
   There are several diagnostic tools for AD and one of the most commonly used is 
Williams’ criteria (8) which include an itchy skin condition plus three or more of the 
following: history of flexural involvement, a history of asthma/hay fever, a history of a 
generalized dry skin, onset of rash under the age of 2 years, or visible flexural 
dermatitis. One well established way to evaluate the severity of disease is by using 
objective SCORing of Atopic Dermatitis (SCORAD). The SCORAD assessment can 
also include an evaluation of pruritus (using visual analogue scale, VAS) and sleep 
disturbance (subjective SCORAD).  
Regarding treatment there are currently rather limited ways of treating AD. The basal 
treatments for patients with mild-moderate symptoms include steroid crèmes, 
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moisturisers and topical calcineurin inhibitors (e.g. tacrolimus, pimecrolimus). The next 
step is often to add treatment with phototherapy and for patients suffering from severe 
AD the systemic treatments available are either methotrexate, systemic cyclosporine or 
azathioprine. There have been and are currently several trials that aim to evaluate the 
effect of specific immunomodulatory therapies in AD. Trials targeting e.g. interleukin 
(IL)-5, CD-20 IgE and tumor necrosis factor (TNF)-α have been performed without 
homogenous results and good clinical response (9). However, there are several ongoing 
trials evaluating new therapies and currently dupilumab (targeting IL-4 and IL-13) 
seem to be one of the most promising (10).  
  
1.2 PATHOGENESIS OF ATOPIC DERMATITIS 
The pathogenesis of the disease is complex and not fully understood but involves a 
disturbance in the skin barrier, abnormal IgE levels and a triggered inflammatory 
response with cytokine release (Fig. 1). 
   Regarding the skin barrier, a mutation in important genes such as the gene encoding 
filaggrin, has been reported (11). Filaggrin is the major source of several major 
components of the natural moisturizing factors in the stratum corneum. The defect 
could also be acquired due to a downregulation by T-helper (TH)-2 cytokines at the 
protein level. Other defects of the skin barrier have been studied in AD, such as tight 
junction formation (reviewed in Wollenberg et al. (12)). Defects in barrier function and 
permeability increase the exposure to allergens and exotoxins. The abnormal IgE 
response in AD is mediated by TH2 cells. During the acute phase of AD Langerhans 
cells are activated by allergens binding to IgE and high-affinity IgE receptor (FceR1). 
Allergen proteins are presented to T-cells and a TH2 profile is induced. These TH2 cells 
regulate and enhance type 1 hypersensitivity responses. 
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Fig. 1. Immunologic pathways in AD. AD inflammation is associated with increased 
Th2 cells in acute skin lesions, but chronic AD results in the infiltration of 
inflammatory IDECs, macrophages (Mφ), and eosinophils. IL-12 production by these 
various cell types results in the switch to a Th1-type cytokine milieu associated with 
increased IFN-γ expression.  
    
Cytokines released by the TH2 cells (e.g. IL-3, IL-4, IL-5 and IL-10) stimulate this 
response in several ways. These include activation and migration of mast cells and 
other inflammatory cells (eosinophils and neutrophils), which in turn are capable of 
causing significant tissue injuring by releasing toxic enzymes, oxygen radicals and 
cytokines (13). In chronic AD lesions there is a tilted balance towards a TH1 response 
and a modulation of the neuropeptides (see further below). The monocytes recruited to 
the skin differentiate into inflammatory dendritic epidermal cells (IDECs), which in 
their turn produce IL-1, IL6 and TNF-α as well as IL-12 and IL-18. These interleukins 
contribute to the switch and the tilted balance to TH1/ TH0 cells which are evident in the 
chronic phase of the disease (7).  
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1.3  THE NERVOUS SYSTEM AND THE SKIN 
The skin is the largest organ in the human body, and it has important functions in 
protection and interaction with the outside environment. Cells forming the skin and 
nervous system have a common origin in the ectoderm during the embryonal 
development.  The skin is richly innervated with a dense network of nerve fibres 
present in both dermis and the epidermis. There are different types of nerve fibres 
connecting the nervous system with the skin, sensory nerve fibres and autonomic nerve 
fibres. The sensory nerve fibres originate from the dorsal root ganglia and are divided 
into subgroups (Aβ, Aδ and C nerve fibres) depending on diameter and speed of signal 
transduction. Aβ fibres are myelinated and the largest (thereby transducing signals the 
fastest), whereas C fibres are not myelinated and smaller and transmit signals more 
slowly. Aδ fibres are thinly myelinated, they send impulses faster than unmyelinated 
C fibres, but more slowly than the thicker Aβ fibres. The nerve fibres in the skin 
transduct stimuli from mechanoreceptors, thermoreceptors and nociceptors that are 
located in the epidermis and dermis. The autonomic nerve fibres constitute a minor part 
of the nerves innervating the skin. These fibres innervate blood and lymphatic vessels, 
glands and hair follicles, and the large numbers of nerves in the dermis may even allow 
vessels to be exposed to neuropeptides without specific innervation (14).  
 
1.4 IMMUNOLOGY OF THE SKIN 
As mentioned in the previous section, the skin, with its various immune cells, plays a 
central part in our defence against microorganisms and other environmental dangers. 
The epidermis and the keratinocytes form the outer layer. The skin hosts microbes 
normally colonizing the skin, also forming a defence to foreign microbes. The skin 
contains a number of different immune cells. In the epidermis there are Langerhans 
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cells and skin-homing T-cells. The keratinocytes are also immunologically active and 
have the ability to mount an immune response by releasing proinflammatory mediators. 
The underlying dermis contains a variety of immune cells including dendritic cells, 
lymphocytes, mast cells and macrophages. When damage or infection occurs the 
recruitment of other immune cells like eosinophils, monocytes and neutrophils takes 
place.  
 
1.5 INTERACTION BETWEEN THE NERVOUS AND IMMUNE SYSTEMS 
There is a close relationship between the nervous and immune systems. Interactions 
between nerves and immune cells play an important role in skin homeostasis and 
disease. The mechanisms underlying this dynamic relationship are not yet fully 
understood.  
   Neuropeptides, including substance P, are predominantly released by sensory C-
fibres that pass through the epidermis in a three-dimensional network with free endings. 
These neuropeptides are capable of directly modulating the functions of many cells 
including keratinocytes (15), mast cells (16), Langerhans cells (17, 18), dermal 
microvascular endothelial cells (19), lymphocytes (20) and macrophages (21) For 
example substance P, at physiological serum concentrations, has an enhancing effect on 
both interferon (IFN)-γ and IL-4 synthesis in stimulated lymphocytes (22).  
 
1.6 STRESS AND NEURO-ENDOCRINO-IMMUNOLOGY  
When a psychologically or a physiologically stressful situation occurs the body 
responds via the systems described above. This has different effects on inflammatory 
processes in the body. The interactions between the systems are complex and only 
partly explored.   
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Several chronic inflammatory skin diseases like AD, psoriasis, urticaria and rosacea 
etc. are reported to be worsened by stress. The stress response has developed from the 
immune system and remains tightly connected and is the oldest response to 
environmental changes (23).  
   In chronic inflammatory skin diseases there are three different systems that could be 
considered to influence the process, by different pathways. The hypothalamic pituitary 
adrenal (HPA) axis via cortisol, the sympathetic (SA) axis via release of adrenalin and 
noradrenalin, and the third axis, also known as the neuropeptides and neurotrophines 
axis (NNA) (23), and which includes the release of neurotransmittors such as substance 
P as a direct neurological response to stress, both centrally and in the periphery.  
   The HPA axis is considered to be the most important pathway in regulating 
peripheral inflammation due to the strongly immunomodulatory actions of 
glucocorticoids. Stressors of both psychological and physiological origin activate the 
HPA axis. It has been shown that peripheral inflammation can activate neurons in the 
hypothalamus through the activation of proinflammatory cytokines and also by 
ascending sensory pathways (reviewed in Maier (24) and Rosenkranz (25)). Another 
study also suggests that peripheral inflammation can have a direct effect on the brain 
through toll-like receptor (TLR)-4 (26). Neurons in the hypothalamus stimulate the 
release of corticotrophine-releasing hormone (CRH) to the anterior pituitary, which 
subsequently leads to the systemic release of adrenocorticotrophic hormone (ACTH). 
The adrenal cortex responds by releasing glucocorticoids.  
   There is no conclusive evidence that corticosteroids are indeed increased or decreased 
during chronic inflammatory diseases. It has been suggested that a lowered level of 
glucocorticoids, e.g. a lowered activity of the HPA axis, would be a part of the 
development of inflammatory and autoimmune diseases. This is considered to be due to 
chronic stress or chronic inflammation that impairs the system (27-29). There have also 
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been several contradictory reports, demonstrating normal or increased levels of ACTH 
and glukocorticoids in animal models of chronic inflammation (reviewed in Harbuz et 
al. (30) and Rosenkranz (25)). The impact of inflammation on the HPA axis has been 
suggested to mediated by substance P, in a rat model (31). 
   The SA axis is the autonomic response to stressors. It is a reflex that increases heart 
rate, blood pressure and the release of adrenaline and noradrenaline from peripheral 
nerve endings. The possibility to regulate bloodflow also affects inflammation per se. 
These catecholamines modulate inflammation through interaction with sensory nerves 
and immune cells.  
   The effect of adrenaline and noradrenaline is generally considered to be anti-
inflammatory due to their inhibitory effects on immune cells and the ability to activate 
CRH-releasing neurones in the hypothalamus. The effect can, however, vary depending 
on the dose of and the type of adrenergic receptor stimulated, and also during which 
step of the immune response the cells are exposed to the neurotransmitter (reviewed in 
Besedovsky and Ray (32), and Rosenkranz (25)). In this context it should also be 
mentioned that a defect parasympathetic system has been suggested to link chronic 
stress and itch (33). This imbalance in the autonomic system results in a prolonged 
activation of the HPA axis as well as modulation of the descending regulating system 
and could cause both central and peripheral sensitization, potentiating itch.  
   The third axis, the NNA axis, is not as well described and understood as the other 
systems mediating stress. Neurotrophines and neuropeptides are released both centrally 
and peripherally as a response to physical or psychological stress (reviewed in 
Liezmann et al. (23)). It has also been shown that neuropeptides can suppress activation 
of the HPA axis (23, 34). In the periphery the release of neuropeptides mediate 
proinflammatory processes (see below in the section Neurogenic inflammation).  
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As discussed above, when considering the development and exacerbation of chronic 
inflammatory diseases, the basal stress levels seem to be of importance. The immune 
system responds to acute stress by increased pro-inflammatory cytokines such as IFN-
γ, resulting in a fast tissue damaging cellular response. Conversely, chronic stress (for 
example in the form of critical life events or increased every day life stress) is different 
and has other effects on the immune system. Chronic stress increases the basal cortisol 
levels and shifts the immune response from cellular to humoral, and the production of 
other interleukins like IL-4 which is a TH 2 cytokine, increases. This is thought to 
facilitate the development of atopic and autoimmune disease, summarized in Liezmann 
et al. (23).  Buske-Kirschbaum et al. has in several articles, see (35) demonstrated a 
blunted response of the HPA axis in patients with atopic disease (AD and asthma). This 
blunted response has, as described above been linked to chronic inflammatory disease 
(e.g., autoimmune and allergic disease). 
 
1.7 TACHYKININS, NEUROGENIC INFLAMMATION AND ATOPIC 
DERMATITIS.  
Neurogenic inflammation is inflammation mediated by the release of inflammatory 
neuropeptides like substance P and calcitonin gene-related peptide (CGRP) from 
afferent neurons. Once released these mediators induce the release of histamine from 
adjacent mast cells. In turn, histamine binding to nerve cells evokes the release of 
substance P and CGRP. Thus, a bidirectional link between histamine release from mast 
cells and neuropeptides is established (Fig. 2).  
  10 
 
Br J Pharmacol. 2013;170:38-45 
Fig. 2. Neurogenic inflammation and itch. Histamine release from mast cells after a 
local stimulus activates neurons communicating with the thalamus and cortex (blue 
line). Next, this creates activation in opposite direction (red line) and induces the 
release of mediators from sensory endings, like SP and CGRP. The SP and CGRP 
released causes further mast cell degranulation, resulting in vasodilatation (flare) 
and the recruitment of other inflammatory mediators. 
 
Focusing on the neurogenic inflammation in the pathogenesis of AD, tachykinins are 
presumably important mediators. Substance P is the most abundant tachykinin peptide 
in mammals and is widely distributed in the peripheral and the central nervous system 
(CNS) of many species (36). Three types of tachykinin receptors (R) have been 
identified to date in mammals: neurokinin (NK)-1, NK-2 and NK-3 receptors. 
Although all endogenous tachykinins can bind to all three receptor types, substance P 
has the highest affinity for NK-1R (37). Neurokinin (NK)-A is encoded from the same 
precursor gene, preprotachykinin (PPT)-A, and this peptide has also been suggested to 
be involved in the inflammatory response, acting mainly through the NK-2R.  
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As mentioned above, stress is a possible trigger for worsening and possible 
development of AD. The exact mechanisms underlying this are not yet known, but the 
release of substance P could be one reason (38). Data indicate that substance P could 
play an important role for stress induction and worsening of AD. It has been reported 
that stress-induced (acute sound stress) worsening of AD is caused by substance P-
dependent neurogenic inflammation, and also shifts the cytokine profile towards TH2 
(39). This further emphasizes the importance of stress in development of allergic 
diseases.  
   An altered number of substance P positive nerve fibres and levels of substance P have 
been reported in the lesional skin of human AD, summarized in Salomon and Baran 
(40). It has also been demonstrated that the number of mast cells containing substance 
P was increased in AD patients (41) and such an increase has also been noted in 
NC/Nga mice (see below) (42). Substance P mediates the degranulation of mast cells. 
The mast cells in turn contain substances such as histamine, cytokines and substance P 
that have different physiological effects. Substance P is also able to specifically bind to 
keratinocytes and to stimulate them to release cytokines such as IL-1, which in turn can 
enhance inflammation(43). Other cell types that contain and can release substance P are 
granulocytes, monocytes, activated lymphocytes(44, 45) and keratinocytes (44) 
 Substance P upregulates TLR-2 in mast cells and potentiates signalling pathways 
associated with TLR-2. This suggests that the immune response to bacterial infections 
in the skin involves the production of substance P and amplification of TLR activation 
(26) In addition, substance P modifies immune responses of atopic T cells to 
Dermatophagoides farinae (in patients sensitized to this mite antigen), by promoting 
proliferation and altering cytokine profiles, indicating that it might modulate the 
clinical manifestations of AD (46). This modulation of the cytokine expression could 
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also, in theory, influence the response to Staphylococcus aureus. The release of 
substance P in the skin has been suggested to contribute to the priming of the immune 
response, so that bacterial infections can be cleared (26). One could speculate that there 
is an excessive release of substance P in the skin as a result of inflammation and stress, 
and a following blunted response to substance P. This blunted response to substance P 
has been suggested in AD (47, 48). This could, in turn, contribute to an impaired 
immunological response and a subsequent reduced defence to microbial infections. 
Suppression of the innate immune system could explain the colonisation with 
Staphylococcus aureus in more than 70% of AD patients (49).  
   NKA has not, to the best of our knowledge, previously been studied in AD per se but 
this neuropeptide has been suggested to be involved in skin inflammation through its 
actions on cell types such as keratinocytes (15). An addition, it has been reported that 
NKA activates dendritic cell-mediated TH1 immune response via NK-2R in a mouse 
model of asthma (50).  
   In this way tachykinins, substance P and NKA can all mediate an immune response, 
suggesting their involvement in the pathophysiology of AD and especially the 
worsening of AD during stress.  
 
1.8 ATOPIC DERMATITIS, PRURITUS AND SUBSTANCE P 
Pruritus is one of the main symptoms in AD and the point prevalence of chronic itch 
has been estimated to be around 87-100% (51). The pruritus is part of the vicious cycle 
of AD resulting in scratching, increased inflammation and impaired skin barrier, 
creating worse inflammation and pruritus. The mechanisms involved in pruritus in AD 
is complex and there is no single cause (reviewed in Mollanazar et al. (51)). Substance 
P is a potent mediator of pruritus and can act both through histamine-dependent and 
histamine-independent pathways. The nerve fibres that are responsible for mediating 
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itch are sensory afferent nerve fibres of C -type. It should be noted, however, that 
pruritus can be induced through several mechanisms, including disruption of the skin 
barrier and an upregulated inflammatory response, resulting in the release of itch-
provoking substances like proteases, histamine, neuropeptides and interleukins. An 
increase of innervation (reviewed in Tominaga and Takamori (52)) and substance P 
positive nerve fibres in lesional skin in AD (summarized by Salomon and Baran (40)) 
have been reported. This could result in an increased ability to react to pruritogenic 
stimuli, and also in an increased release of substance P. There is also a possibility of a 
peripheral sensitisation as well as an activation of centres related to pruritus in the CNS 
(reviewed in Mollanazar et al. (51) and Yosipovitch and Papoui (53)).  
   As mentioned above, substance P is an important pruritic mediator in humans and 
mice (54, 55). When substance P is released it binds to NK-1R on mast cells, 
keratinocytes and cutaneous nerve endings, resulting in the release of pruritogenic 
mediators. There are several receptors that have the ability to mediate itch. Of these, the 
transient receptor potential (TRP) superfamily is a class involved in sensory 
perception, including itch, as well as other various sensory modalities (e.g. chemical 
and thermal) as reviewed in Mollanazar et al. (51). Several subfamilies of the TRP 
superfamily are expressed in normal human skin and have been implicated in itch: 
TRPV1, TRPA1, and TRPM8.  Histamine causes activation of TRPV1 and result in 
the perception of itch, in contrast to TRPA1 that seems to be activated by non-
histaminergic mediators. Another family that mediates itch via non-histaminergic 
pathways are the protease-activated receptors (PAR), PAR 2 and PAR4. As the name 
suggests these receptors are activated by proteases, released during inflammation in 
the skin. In this context, substance P has the ability to interfere in the different 
pathways mediating itch. For example substance P causes mast-cell degranulation and 
the release of histamine, resulting in activation of the histaminergic pathway. 
  14 
Furthermore, the release of proteases from mast cells and other inflammatory cells 
can activate non-histaminergic pathways by the receptors described above. The 
binding of substance P to NK-1R on nerve endings in the dorsal horn could also 
activate neurons transducing itch, indicating substance P to be an important mediator 
at different levels (56). Substance P is, as described above, a proinflammatory peptide 
and can thereby also indirectly worsen the itch by worsening the inflammation, 
resulting in a local increase of all the pruritogenic mediators mentioned above. In 
addition, an increased inflammation affects the skin barrier, and a damaged skin 
barrier per se seems to be able to cause itch, possible by the TRPA1R (57). 
Keratinocytes are also able to mediate itch via sensory nerve fibres and factors like an 
impaired skin barrier, epidermal inflammation and the release of substance P itself 
can affect the keratinocytes. Consequently, substance P can induce pruritus, even 
though it might be indirectly (51).  
   Furthermore, it has been shown that the scratching behaviour in a mouse strain is 
inhibited by a NK-1R antagonist (55). Studies have been made using a NK-1R 
antagonist, aprepitant (Emend ®), on different types of pruritic conditions in humans 
with promising results (58).  
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2 AIMS 
 
The aim of the study was to investigate the role of tachykinins in the pathogenesis of 
AD, pruritus and worsening during stress. This has been the focus of the following 
studies: 
 
I. To examine nerve fibres and axonal growth in the skin in a mouse model of AD and 
chronic mild stress, and to determine if any modulation in eczematous skin and/or 
modulation is due to chronic mild stress.  
  
II. To examine a possible connection between chronic mild stress and changes in the 
expression of substance P and its receptor NK-1 in the skin and stress-related brain 
regions, in the same mouse model. 
 
III. To study the expression of tachykinins; substance P, NKA and the NK-1R, in 
human AD skin, as well as possible correlations to clinical and psychodemographic 
parameters.  
 
IV. To examine the effect of a substance P antagonist in patients with 
moderate/severe AD.  
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3 MATERIALS AND METHODS 
 
3.1 ANIMAL STUDIES (I-II)  
3.1.1 Mouse model (I-II) 
One often-used animal model to obtain an AD-like lesion is the NC/Nga mouse. Itching 
dermatitis, being similar to AD in humans, arises spontaneously at the age of 8 weeks 
in NC/Nga mice kept in a non-sterile environment. In sublines of this strain eczema is 
developed by challenging the skin with a mite antigen (59). These animals constitute a 
good model for studying the processes in AD that takes place in the skin, and for 
comparative studies of human pathogenesis (60) . 
 
3.1.2 Chronic mild stress (I-II)  
A modification of the chronic mild stress procedure described by Lanfumey et al.(61) 
was used. A Scantainer box type 50-SCNT-Z11 (Scanbur AS, Köge, Denmark) was 
used to home the mice and different stressors such as reversed light/dark cycle, 
confinement to small cages, one period of continuous overnight illumination, 
overcrowding of the animals, one overnight period of wet soil, repeated periods of 
cage-tilting (30°) and short periods of food and water deprivation were employed. 
Chronic mild stress was maintained for 8 weeks, at which point the immunization 
protocol was initiated and stress maintained for another 4 weeks, after which the mice 
were sacrificed. 
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3.1.3 Immunization (I-II) 
The mice were divided into 3 groups (8 mice per group). One group was stressed and 
immunized (stressed eczematous, SE). A non-immunized control group was stressed 
(stressed control, SC), with the mice being painted on the ears using the vehicle only, 
whereas a second immunized group was not exposed to stress (non-stressed 
eczematous, NSE). Eczema was induced (also in the NSE group) by painting their ears 
with a mite antigen, Dermatophagoides pteronyssinus (Allergon, Ängelholm, Sweden), 
which had been dissolved in phosphate buffered saline (PBS) and 0.5% Tween 20 at a 
concentration of 10 mg/ml. All mice were maintained on a 12 h light/dark cycle with a 
temperature between 18 and 22oC.   
 
3.1.4 Samples (I-II)  
The animals were sacrificed after 12 weeks and the ear diameters were measured using 
a calliper (Kroeplin, Schluchtern, Germany). Blood samples were collected at 10 a.m. 
and plasma corticosterone was measured using a Corticosterone RIA kit (RS 490 11, 
IBL, Hamburg, Germany).   
   Tissue samples from the ears and brains were subjected to reverse transcription 
polymerase chain reaction (RT-PCR) and immunohistochemistry in order to analyse 
changes in expression of substance P or NK-1R. For RT-PCR samples were snap-
frozen on dry ice and for immunohistochemistry they were fixed in 4% formalin with 
0.2% picric acid for 2 h at 4°C. The immunohistochemistry samples were then rinsed 
with 0.1 mol/L phosphate buffer containing 10% sucrose for at least 24 h. Tissues were 
next embedded in Tissue-tek (Sakura Finetek, Zoeterwoude, The Netherlands) and 14 
µm thick skin and sagittal brain cryostat (Microm, Heidelberg, Germany) sections were 
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mounted on glass slides (SuperFrost Plus, Menzel-Gläser, Freiburg, Germany) and 
stored at -70°C.  
 
3.1.5 RT-PCR  (II) 
RT-PCR was used to determine PPT-A and NK-1R mRNA from mice skin and brain. 
   Total RNA was extracted from the skin and brain samples (Aurum Total RNA Fatty 
and Fibrous Tissue Kit, Bio-Rad, Sundbyberg, Sweden). First strand cDNA for PCR 
was generated from 1µg of total RNA using the manufacturer´s kit (Bio-Rad). Primers 
for amplification were as follows: PPT-A (289 bp) sense 
ACCTGCTCCACTCCTGCACCG CGGCCAAG, antisense 
GAACTGCTGAGGCTTGGGTCTTCGGGCGAT, NK-1R (440 bp) sense 
TTCCCCAACACCTCCACCAA, antisense AGCCAGGACCCAGATGACAA. PCRs 
were performed in a thermal cycler (GeneAmp PCR System 2700, Applied 
Biosystems, Stockholm, Sweden) using experimental conditions that had been set up in 
previous experiments. After migration the bands corresponding to the amplified 
products (characterized on the basis of their molecular weights) were photographed and 
their sizes analysed (Image J program). 
 
3.1.6 Immunohistochemistry (I-II) 
Sections were prepared as described above followed by immunohistochemistry for 
protein gene product (PGP) 9.5, growth associated protein (GAP)-34, substance P, 
NK-1R and tryptase. Antibodies were incubated for 40 min with 10% normal goat 
serum (S-100, Vector, Burlingame, CA, USA), in order to minimize non-specific 
protein binding. The sections were then incubated with rabbit polyclonal antibodies 
directed against PGP 9.5 (dilution 1:10 000; RA95101, UltraClone, Cambridge, 
  20 
England), GAP-43 (1:3 000; AB5220, Chemicon, Temecula, CA, USA), substance P 
(T-4107; 1:10 000, Bachem, St Helens, England), NK-1R (NB 300-101; 1:5 000, 
Novus Biologicals, Littleton, CO, USA) or tryptase (1:10 000) a kind gift from Prof. I. 
Harvima, Kuopio, Finland) at 4°C overnight. Thereafter, incubation with biotin-labeled 
goat anti-rabbit (BA-1000, 1:200) as the secondary antibody was performed for 40 min 
at room temperature followed by treatment with the fluorochrome Cy2-labelled 
streptavidine (PA42001; 1:2 000, Amersham Pharmacia Biotech, Uppsala, Sweden), 
also for 40 min at room temperature. All antibody solutions were diluted in PBS 
containing 1 % bovine serum albumin (BSA) (A9418, Sigma-Aldrich, Stockholm, 
Sweden) prior to use.  
   Acetylcholinesterase histochemistry was used to confirm the location of amygdala, 
and to match it with the expression of substance P and NK-1R on adjacent sections. 
   As negative controls, either the primary antibodies were omitted or normal rabbit 
serum (X0936; Dako, Glostrup, Denmark) was used instead of the primary antibody. In 
addition, pre-adsorbtion of substance P and NK-1R antibodies was performed using  
10-6 mol/L of substance P (H1890, Bachem) and 4 µg/ml of NK-1R (ab92818, Abcam, 
Cambridge, UK), respectively. These control experiments resulted in a loss of, or a 
substantially decreased, signal. 
   Finally, the sections were rinsed in PBS and mounted with Kaiser´s glycerol gelatin 
(Merck, Darmstadt, Germany).  
 
3.1.7 Microscopy (I-II) 
Immunoreactivities were observed and documented by epifluorescence (Zeiss 
Axioskop 2 MOT microscope, Carl Zeiss, Stockholm, Sweden).  
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3.1.7.1 Study I 
The PGP 9.5 stained sections were analysed using a software program (see Image 
analysis 2.I.7.3). Twenty-four pictures representing four sections were taken per 
mouse. All areas of the sections were represented except the ends. 
GAP-43 positive nerve fibers were counted manually for practical reasons due to the 
low contrast between the positive nerves and the surrounding tissue, which influenced 
the threshold settings for detection of the fluorescence. Nerve fibers that crossed the 
dermoepidermal junction were included in the layer in which most of the nerve fiber 
was found. Fibers that were clearly connected to hair follicles or glands were not 
included. From the GAP-43 stained sections 2 areas per section (8 per mouse) were 
counted. The microscopic evaluation was performed by one observer (LL). 
 
3.1.7.2 Study II 
Substance P-labelled brain sections were subjected to image analysis (see Image 
analysis 2.I.7.3). Regarding prefrontal cortex and amygdala, two selected areas per 
mouse were analysed and the mean was calculated, while one area per mouse was 
analysed for the CA1 and CA3 regions of hippocampus.  
   Substance P positive nerve fibres in the skin were counted manually due to the low 
contrast between positive nerves and surrounding tissue, which prohibited satisfactory 
signal-to-noise discrimination with our image analysis program. From the substance P-
labelled skin sections 2 areas (microscopic fields) per section (8 per mouse) were 
counted. The same number of areas was chosen for tryptase-labelled sections. Mast cell 
degranulation was assessed using a semiquantative method (low = 1, moderate = 2, 
high = 3). The skin sections immunolabelled for NK-1R were also analysed using a 
semi-quantitative method, where the intensity (as above) of the immunoreactivity was 
microscopically evaluated on coded slides by one observer (LG).  
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3.1.7.3 Image analysis (I-II) 
Appropriate software (Easy Image Analysis, Bergström Instruments, Solna, Sweden) 
was applied to analyse the amount of substance P immunoreactivity in digital images of 
the brains. Results are presented as area fraction (ratio of specifically immunoreactive/ 
non-fluorescent area).  
 
3.2 HUMAN STUDIES (III-IV) 
3.2.1 Study design (III) 
A cross-sectional study was performed to investigate the expression of tachykinins 
substance P, NKA and the NK-1R in human skin of AD, as well as possible 
correlations to clinical and psychodemographic parameters. 
 
3.2.2 Study design (IV) 
An open randomized trial was conducted with an active treatment period of 7 days in 
order to investigate the effect of aprepitant on extent of disease and pruritus in AD, and 
also to investigate if there would be any effect on depression and anxiety. All 
participants received oral and written information about the study and voluntarily 
signed an informed consent. The study was conducted during the period from October 
2013 to March 2015. 
    Randomization was performed using a randomization list with no stratification. The 
nurses who evaluated SCORAD in the patients were unaware of which treatment group 
the patients belonged to.  
    The patients received 80 mg of aprepitant daily for 7 days in addition to topical 
treatment with a moisturizer and a moderately strong steroid cream (hydrocortisone 
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butyrate; Locoid ®). The control group received only the topical treatment. The 
patients were monitored regarding extent of the disease (SCORAD), their degree of 
pruritus, as well as anxiety and depressive scores (see below) using Montgomery-
Åsberg Depression Rating Scale-Self assessment (MADRS-S).  
 
3.2.3 Patients  (III-IV) 
3.2.3.1 Study III 
Twenty-eight adult AD patients, 18 females and 10 males, mean age of 29.5 years 
(range 19-48 years) were included in the study. The patients were recruited among 
referred patients to our clinical department. To be included in the study the patients 
should have an ongoing AD according to Williams et al. (8) and they should not 
receive systemic therapy (including phototherapy and antihistamines) during the study, 
or within one month prior to inclusion. All patients included, except one, fulfilled all 
procedures; one female did not complete the questionnaires. 
   Ten healthy individuals, 5 males and 5 females (mean age 37.7 years, range 20–61 
years), with no previous atopic manifestations such as hay fever, asthma or AD, were 
recruited as controls for the histochemical parameters. 
 
3.2.3.2 Study IV 
Forty-one adult patients between 20-50 years of age, both females (n=23) and males 
(n=18), were included in the study. The patients attended our out-patient unit at the 
Department of Dermatology, Karolinska University Hospital, Solna, Sweden. The 
patients had a moderate – severe (measured as SCORAD >20) AD, and diagnosis was 
determined according to Williams´ criteria (8). To be included they needed to be 
otherwise healthy. Except for contraceptives they should have no other medication, 
such as regular asthma and allergy medication. Other exclusion criteria were dark skin 
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and skin infections. Patients who were pregnant, breast-feeding or planning to become 
pregnant were also excluded.  
 
3.2.4 Extent of disease (III-IV) 
The extent of the disease was assessed using SCORAD (62). Both objective and 
subjective SCORADs were included.  
 
3.2.5 Pruritus (III-IV) 
The degree of pruritus was assessed using a visual analogue scale (VAS) in which 
patients rate their own pruritus for the last three days using a scale 0-10 (0 = no 
pruritus, 10 = worst imaginable pruritus). In addition, in study IV, the patients 
registered scratching movements per day using a manual counter (Clas Ohlson, Insjön, 
Sweden). The patients were asked to register either a scratching movement or in the 
case of several movements, an episode.  
  
3.2.6 Psychodemographic measurements (III-IV) 
 In study III SSP (Swedish Universities Scales of Personality) (63), a 91-item 
questionnaire, was used to evaluate patients personality traits. The questionnaire was 
completed by the patients themselves and then analysed regarding somatic trait anxiety, 
psychic trait anxiety, stress susceptibility, impulsivity, trait irritability, lack of 
assertiveness, verbal trait aggression and physical trait aggression. Absolute scale 
values were calculated.  
   To assess the level of depressive symptoms in study III and IV, MADRS-S (64) was 
used, describing the patient´s current psychological status.  
  25 
In study IV, to assess depression and anxiety the Hospital Anxiety and Depressive 
scale, HAD (65) was used. This is a simple self-assessment questionnaire that reflects 
the patient's mood. It assesses anxiety and depression simultaneously. 
 
3.2.7 Skin sample processing (III)  
Biopsies, 3 mm in diameter, were taken from lesional skin (characterized by dryness, 
papules, and often lichenification) of the bend of the arm, and from non-lesional skin 
from the sacral region. Biopsies from healthy control persons were also taken from the 
sacral region. No topical steroids should have been used for at least 14 days on these 
areas prior to inclusion in the study. The biopsies were then fixed and sectioned as for 
the mouse tissue specimens described above (1.1.3) 
 
3.2.8 Immunohistochemistry (III) 
The immunohistochemistry process was performed for substance P and NK-1R as 
described in the previous section (1.1.5). Regarding NKA the antibody used was T-445; 
(1:5 000, Bachem) 
Double staining was performed in order to characterize the cellular phenotype 
expressing substance P, NKA and NK-1R. The sections were incubated with the 
primary antibodies, followed by secondary biotinylated antibody as above and Alexa 
SAV 555 red or Alexa 488 green (1:1 000, Life Technologies, Stockholm, Sweden). 
Monoclonal antibodies specific for CD3 (555916; 1:25, BD Pharmingen, Franklin 
Lakes, NJ, USA) or tryptase (MAB1222 ;1:1 000, Chemicon) were then added, 
followed by Alexa 488 green or Alexa 594 red (1:1 000). The substance P positive cells 
were mostly positively stained for CD3, indicating that majority of cells were 
lymphocytes. NKA positive cells were mostly positive for tryptase. The majority of 
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NK-1R positive cells were positively stained with tryptase, indicating these cells to be 
mast cells.  
 
3.2.9 Microscopy (III) 
General histopathological changes, hyperkeratosis, acanthosis and degree of 
inflammation (infiltration of inflammatory cells in the dermis) were graded semi 
quantitatively, 0-3 (0 = normal appearance, 1 = mild, 2 = moderate and 3 = strong).  
   Sections were counted manually by one observer (LL). For the absolute numbers of 
substance P and NKA positive cells and nerve fibres, and NK-1R positive (mostly 
dendritic) cells, the mean value per section was calculated and standardized to 2.5 fields 
of vision. Four sections per biopsy were analysed. The semi-quantitative evaluations 
for NK-1R cellular epidermal infiltration and NKA degranulation were graded 0-3 (0 = 
negative, 1 = mild, 2 = moderate and 3 = strong). NK-1R cell degranulation was graded 
0-1 (0= none, 1= positive). 
 
3.2.10 Statistics (I-IV) 
3.2.10.1 Study I-II 
For statistical analysis the Student´s t-test or the Mann-Whitney test were used 
depending on distribution of the data. In addition, Chi-square was used to analyse 
semiquantitative data. A p- value of < 0.05 was considered statistically significant. 
 
3.2.10.2 Study III 
The numerical calculations for substance P, NKA and NK-1R were calculated using 
Student’s t-test or Mann-Whitney test (depending on distribution of the values). For 
semiquantitative evaluation Chi-square was used. Correlations between the different 
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parameters were measured using Spearman´s or Pearson´s tests (depending on 
distribution of the values). Differences were considered to be statistically significant 
when p < 0.05.  
 
3.2.10.3 Study IV  
Statistical analysis was performed for all patients included in the study (intention to 
treat, IIT), as well as on values for patients that would continue in the study as planned 
by protocol (per protocol, PP).  Lost values would be included in the IIT-analysis using 
the principle last value carried forward. Statistical comparisons in order to test 
differences between two independent groups were made by use of the Student’s t-test 
for uncorrelated means, after validation for normal distribution by use of the Shapiro 
Wilk test. The dimension of the study was calculated to provide 80% power to detect a 
difference in SCORAD-improvement of 3 points at the 5% significant level (2-sided).  
 
3.2.11 Ethical permission (I-IV) 
Ethical permissions were obtained for all of the studies. Number N440/04 for study I-II, 
and 2010/800-31/3 for study III. The protocol for the fourth study was approved both 
by the local ethics committee, number 2013/1158-31/3, and by the Medical Products 
Agency. 
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4 RESULTS 
 
4.1 ANIMAL STUDIES (I-II)  
4.1.1 Study I 
4.1.1.1 Combination of chronic stress and eczema results in decreased corticosterone 
levels and increased degree of inflammation 
To estimate levels of chronic stress, corticosterone levels were determined. At the 
termination of the experiment the SE group exhibited lower corticosterone levels, 
496.4 ± 221.5 (mean±SD) ng/ ml, compared to the other groups, NSE 738.6 ± 232.1, 
and SC 805.2 ± 144.4 ng/ml.  
   To estimate the degree of inflammation the diameter of the ears in millimetre was 
used. The results showed that the diameter of the ears was larger in the SE group, 
0.49 ± 0.11 mm, compared to the NSE, 0.36 ± 0.13 mm (p < 0.01) and the SC, 0.23 ± 
0.00 mm (p < 0.001), indicating a higher degree of inflammation. 
 
4.1.1.2 Chronic mild stress has an additive effect in eczematous skin and results in 
decreased innervation 
To investigate the impact that inflammation and stress could have on innervation, 
expression of PGP 9.5 was analysed. In the epidermis there was a decrease (p < 0.01) 
in the PGP 9.5 positive nerve fibres in the SE, measuring area fraction, 0.8 ± 0.3, 
compared to the NSE group (2.4 ± 1.2) and the SC group (2.5 ± 1.2). This was also 
true for the dermis where there was a decrease of the PGP 9.5 positive nerve fibres in 
the SE (1.3 ± 0.3) compared to the NSE group (2.9 ± 1.2, p < 0.01) and the SC group 
(3.4 ± 0.9, p < 0.001). 
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4.1.1.3 Inflammation decreases newly formed nerve fibres in skin 
To investigate newly formed nerve fibres analysis of GAP-43 was performed. In the 
epidermis the results revealed a decrease (p<0.01) in the GAP-43 positive fibres in the 
SE (40.7 ± 20.5 fibres per section) compared to the SC group (75.9 ± 20.4). The NSE 
(48.1 ± 28.8) compared to the SC group also showed a decrease (p<0.05). There was no 
difference in the SE group compared to the NSE group. In the dermis similar results 
were observed with a decrease (p < 0.05) in the number of GAP-43 positive dermal 
fibres in the SE (108.6 ± 29.7 fibres per section) compared to the SC group (133.5 ± 
31.8). The value for the NSE group was 122.9 ± 27.5.  
 
4.1.2 Study II 
4.1.2.1 RT-PCR in skin – chronic mild stress further increases NK-1R in eczematous 
skin. 
To analyse the expression of substance P and NK-1R, on RNA-level, PCR was 
performed.  
   No difference in the PPT-A mRNA signals could be determined between the three 
groups. 
   An increased NK-1R signal (p < 0.05) was found in SE (0.95, median; 0.22 quartile 
deviation), compared to SC (0.71; 0.17) mice. A strong tendency towards an increase (p 
= 0.06) was also found in SE compared to NSE (0.73; 0.45) mice. 
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4.1.2.2 Immunohistochemistry in skin - chronic mild stress further decreases 
expression of substance P and increases mast cell activity in eczematous skin  
 
To further evaluate the impact of stress and inflammation in skin investigation of 
expression of substance P, NK-1R and mast cells in skin was performed. A 
significantly lower (p < 0.05) number of substance P positive fibres/area in dermis and 
epidermis was evident in the SE group (0.8; 0.3), compared to SC (1.4; 0.9) group. The 
corresponding value for the NSE group was (1.6; 1.5), suggesting that the lower 
number of substance P fibres in the SE group was caused by a combination of mild 
stress and immunization. 
   The mean intensity of NK-1R immunoreactivity was higher in epidermis of NSE and 
SE mice (NSE: 2.2 ± 0.7, mean ± SD, SE: 2.0 ± 0.8), compared to SC mice (1.7 ± 0.5), 
although these differences did not reach statistical significance. Neither NK-1R 
immunoreactive inflammatory cells nor nerve fibres were observed. 
   An increase of tryptase immunoreactive mast cells/area in dermis in SE (89 ± 18) 
compared to both SC (52 ± 17) and NSE (63 ± 26) mice (p < 0.001 and p < 0.05, 
respectively), was observed. Mast cells also showed increased (p < 0.05) degranulation 
in SE (2.8 ± 0.7) compared to both NSE (1.8 ± 0.9) and SC (1.6 ± 0.7) mice. 
 
4.1.2.3 RT-PCR in brain – no differences found 
No significant differences or stable trends in RNA expression levels were found in the 
three groups for PPT-A or NK-1R. 
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4.1.2.4 Immunohistochemistry in brain – combination of chronic mild stress and 
eczema decreases substance P expression in hippocampus 
In order to investigate the expression of substance P and NK-1R in the central nervous 
system, and discover possible modulations of inflammation and chronic mild stress, 
analysis was made of prefrontal cortex, amygdala and hippocampus.  
Substance P immunoreactivity was abundantly evident in the prefrontal cortex. In the 
amygdala the most prominent substance P activity occurred in the central nucleus 
which prompted further analysis. We recorded more immunoreactivity in the medial 
compared to the lateral hippocampus, and hence decided to analyse that part of the 
hippocampus. The CA1 and CA3 areas of medial hippocampus were analysed 
separately.  
     In CA1 a tendency toward a decrease (p = 0.08) in area fraction of substance P 
positive nerve fibres and neuronal cells was apparent in SE, 3.2 (median); 3.9 (quartile 
deviation), compared to NSE (7.8; 2.9) mice. The area fraction was 5.2; 5.4 in SC mice. 
In CA3, a decrease (p < 0.05) of substance P positive nerve fibres and neuronal cells 
was seen in SE (0.6; 0.7) compared to NSE (1.8; 1.5) mice. In addition, a tendency 
toward a decrease (p = 0.06) in SE compared with SC (1.1; 0.5) mice was noted.  
     In the prefrontal cortex there was no significant difference between the groups in 
terms of amounts of substance P positive nerve fibres and neuronal cells, the area 
fractions being (0.90; 1.35), (1.33; 0.35), (1.07; 0.85), for SE, NSE and SC, 
respectively. 
     In the amygdala there was no significant difference between the groups with regard 
to amounts of substance P immunoreactive nerve fibres. The area fractions were (3.84; 
3.17), (7.90; 3.43), (4.13; 2.95), for SE, NSE and SC, respectively. 
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NK-1R immunoreactivity was not detected in prefrontal cortex, amygdala or 
hippocampus, in the different groups. NK-1R positive nerve fibres/cells were, however, 
observed in other parts (e.g. striatum) of the brain. 
   A few tryptase positive mast cells could be observed throughout cerebrum, 
particularly located around vessels.  
 
 
 
4.2 HUMAN STUDIES (III-IV) 
4.2.1 Study III  
 
4.2.1.1 Extent of disease  
The extent of the disease was assessed using SCORAD. Both objective and subjective 
SCORAD were included. The mean objective SCORAD among included patients was 
42.3 ± 11.5 (mean ± SD) and subjective SCORAD 51.6 ± 13.4.   
 
4.2.1.2 Pruritus 
The degree of pruritus was assessed using VAS, in which the patients rated their own 
pruritus, for the last three days. The pruritus intensity among the patients was 5.2 ± 2.4. 
 
4.2.1.3 Psychodemographic data  
Psychodemographic data were analysed in order to establish correlations to clinical or 
histological parameters. The score for somatic trait anxiety was 15.1 ± 4.3, psychic trait 
anxiety 15.2 ± 3.8, and stress susceptibility 16.3 ± 4.1. The depression score (measured 
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using MADRS-S) was 8.0 ± 6.5. Impulsivity score was 17.0 ±3.9, verbal trait 
aggression being 13.5 ± 4.2, and physical trait aggression 12.7 ± 4.7.  
 
4.2.1.4 General histopathological findings – increased inflammatory signs in lesional 
skin 
The skin samples were analysed in order to investigate the histological appearance. The 
results showed that the degree of acanthosis was elevated (p < 0.001), 2.1 ± 0.8, in 
lesional skin compared to non-lesional, 0.6 ± 0.8, skin, and control, 0.6 ± 0.5, skin (p = 
0.001). The degree of inflammation was also elevated (p < 0.001) in lesional, 2.4 ± 0.7, 
compared to non-lesional, 1.1 ± 0.8, skin, and there was also a strong tendency (p = 
0.06) to increase compared to control skin, 0.3 ± 0.5.    
 
4.2.1.5 Immunohistochemistry – increased expression of substance P nerve fibres in 
lesional skin 
The skin samples were further stained for tachykinins and NK-1R in order to establish 
any differences between AD and control skin and to investigate if there would be any 
correlations to psychodemographic or clinical parameters.   
   The immunohistochemical analysis revealed an increase (p < 0.01) in substance P 
positive fibres in lesional, 2.1 ± 2.3, compared to non-lesional, 0.7 ± 1.0, skin, and an 
increase (p < 0.05) in control 1.4 ± 1.1 compared to non-lesional skin. Regarding 
substance P positive cells, the values for lesional skin were 91 ± 77, non-lesional 58 ± 
38 and control skin 48 ± 20, the differences being not statistically significant.  
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4.2.1.6 Immunohistochemistry – increased expression of NKA positive cells and fibres 
in lesional skin 
For NKA positive fibres the immunohistochemical analysis resulted in an increase (p < 
0.01) in lesional, 2.8 ± 2.4, compared to non-lesional, 1.0 ± 1.3, skin. Control was 1.4 ± 
1.4. There was an increase of NKA positive dendritic cells, in the dermis in lesional, 
2.1 ± 5.9, compared to both non-lesional, 0.3 ± 0.8 (p < 0.01), and control, 0.2 ± 0.6 (p 
< 0.05), skin.  
   The degranulation of NKA positive cells was increased (p < 0.05) in lesional, 1.0 ± 
1.1, compared to control, 0.2 ± 0.6, skin, and a tendency (p = 0.06) to an increase 
compared to non-lesional skin, 0.4 ± 0.7.  
 
4.2.1.7 Immunohistochemistry – increased degranulation and epidermal infiltration 
of NK-1R positive cells in lesional skin 
There were no differences for NK-1R positive cells, mostly dendritic between lesional, 
57 ± 35, non-lesional, 58 ± 30, and control, 61 ± 18, skin. An increased (p < 0.05) 
degranulation of NK-1R positive cells was observed in lesional, 0.5 ± 0.5, compared to 
control skin, 0.1 ± 0.3, skin. The non-lesional skin value was 0.3 ± 0.5. There were also 
epidermal infiltrating mononuclear cells with NK-1R positivity with an increase (p < 
0.001) in lesional, 0.5 ± 0.8, compared to non-lesional, 0.0 ± 0.0, skin, and a tendency 
(p =0.06) to increase in lesional compared to control skin 0.0 ± 0.0.   
 
4.2.1.8 Correlations – a correlation between NK-1R positive cells and depression 
A significant correlation between pruritus and somatic trait anxiety (r  = 0.48, p < 0.05) 
and also a tendency to a correlation to stress susceptibility  (r  = 0.38,  p = 0.06) were 
noted, but not with any of the presently studied histopathological parameters in either 
lesional nor non-lesional skin.   
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We could also observe a correlation between NK-1R cells and acanthosis (r = 0.49, p < 
0.01) and inflammation (r = 0.44, p < 0.05), respectively, in lesional skin.  
   Futhermore, there were correlations between acanthosis and NKA positive cells (r = 
0.45, p < 0.05) and NKA cell degranulation (r = 0.43, p < 0.05) in non-lesional skin. In 
addition, a tendency to correlation (r = 0.36, p = 0.06) between NKA positive cells and 
inflammation in non-lesional skin was determined. 
    Correlations between depression score and NK-1R cells in lesional (r =0.43, p < 
0.05) and non-lesional skin (r = 0.54, p < 0.01), were found.  
   Regarding impulsivity there was a correlation (r = 0.51, p < 0.01) with NKA positive 
cells and a tendency to a correlation (r = 0.37, p =0.06) with NKA degranulation, both 
in lesional skin.   
     No correlation was observed for any of the aggressive personality traits. 
 
4.2.2 Study IV 
4.2.2.1 Extent of disease – both groups showed a decrease in SCORAD 
In order to investigate the effect of aprepitant on AD, the extent of disease was 
evaluated by SCORAD. In the aprepitant-treated group, the extent of AD measured by 
SCORAD decreased (p < 0.01) from 40.5 ± 12.0 (mean ± SD) to 32.0 ± 11.2, as well as 
in the control group, where SCORAD decreased (p < 0.001) from 37.0 ± 11.3 to 26.7 ± 
14.7.  For subjective SCORAD (S-SCORAD) there was a decrease (p < 0.001) in the 
treatment group as well as in the control group, from 49.0 ± 14.1 to 38.1 ± 12.6 and 
from 47.7 ± 13.7 to 33.0 ± 18.9, respectively. There were no significant differences 
between the groups.  
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4.2.2.2 Pruritus – both groups showed a decrease of pruritus 
For evaluation of pruritus evaluation with VAS and scratching movements was made. 
VAS in the treatment group was 5.5 ± 2.1 at the inclusion and decreased (p < 0.05) to 
3.8 ± 2.2 at the end of treatment visit (Day 7) as well as in the control group, 6.7 ± 2.2 
to 4.1 ± 3.0 (p = 0.001). In the treatment group there was a decrease (p < 0.05) of 
scratching movements from 77.3 ± 97.9 to 48.3 ± 62.6 and in the control group there 
was a tendency (p = 0.07) to a decrease from 65.0 ± 100.9 to 34.7 ± 45.0. There were 
no significant differences between the groups at any of the time points, Day 3, Day 5 or 
Day 7.  
 
4.2.2.3 Total IgE – increases in the group treated with aprepitant 
To determine if aprepitant also could affect IgE levels analysis of IgE was made before 
and after treatment. In the treatment group there was an increase (p < 0.05) from 903.7 
± 1391 to 937.9 ± 1403, after treatment. In the control group the mean value before 
treatment was 876.5 ± 1934 and after treatment 821.1 ± 1754.  
 
4.2.2.4 Depression and anxiety score – decrease of depression in both groups 
As aprepitant penetrates the blood-brain barrier and also affects NK-1R in the CNS we 
therefore considered it of interest to also evaluate depression and anxiety before and 
after treatment. In both the treatment group and the control group there was a decrease 
(p < 0.05) in MADRS-S score from 5.6 ± 4.9 to 4.0 ± 5.3 and from 9.3 ± 8.9 to 6.5 ± 
5.9, respectively. A decrease (p < 0.01) of depression score in HAD was also seen in 
the control group, from 3.8 ± 2.7 to 2.4 ± 2.3. This was not significant in the treatment 
group, where results were from 1.9 ± 2.1 to 1.8 ± 2.4. Measuring anxiety, there was a 
decrease in the control group from 6.6 ± 4.8 to 4.8 ± 3.7 (p < 0.05), but no difference 
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was evident in the treatment group, where values were 3.4 ± 4.1 before and 3.5 ± 3.2 
after the treatment period.  
 
4.2.2.5 Safety – the treatment was generally well tolerated 
The patients were monitored in regard to adverse events (AEs) during the study. 
Thirteen out of the 21 aprepitant-treated patients reported adverse events (headache, 
fatigue, dizziness, elevated liver enzymes, palpitations, dyspné, changed ability to react, 
obstipation, stomach ache, periocular dermatitis, and erectile dysfunction). All AEs 
were considered mild to moderate. All AEs were transient except for one case of 
elevated liver enzymes. 
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5 DISCUSSION 
 
5.1 ANIMAL STUDIES (I-II) 
In the first two studies an animal model of mild chronic stress and eczema was used. 
The chronic mild stress form seems relevant from a patient´s perspective. The minor 
everyday stressors are often what bother the patients most and many patients 
experience a worsening of the disease as a physical sign of the stress they experience. 
Substance P is an important mediator of both stress and inflammation and has a central 
role in regulating the activity of these pathways and the communication between them. 
Chronic stress has been shown to result in neurogenic inflammation in the intestines of 
the rat (66). Another study, in tree shrews, has investigated the effects of chronic stress 
in the form of daily psychosocial conflict. This resulted in morphological modulations 
of the hippocampus, which could be prevented by treatment with a substance P 
antagonist (67). Furthermore, depression has been shown to result in elevation of both 
central and peripheral levels of substance P (68).  
   The present study showed that the SE group had lower corticosterone levels 
compared with the other groups. This could indicate that the SE group had a blunted 
stress response, a suppression of the HPA axis due to the combination of eczema and 
chronic stress. A similar condition of blunted HPA response has been reported in AD 
in humans (35). 
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5.1.1 Skin (I-II) 
In the skin the combination of stress and eczema resulted in a higher degree of 
inflammation, noted as larger ear diameter in this group compared to the other. This 
is in concordance with another study reporting increased inflammation as a result of 
stress (69).  
   Further investigations of the skin revealed a decrease in innervation (PGP 9.5 
positive nerve fibres) in the SE compared to the NSE mice, in both the epidermis and 
dermis. This might indicate that the stress would have a negative effect on 
innervation. A decrease in newly formed nerve fibres (GAP-43 positive) was also 
seen in the SE compared to the SC group in both the epidermis and dermis, indicating 
that the inflammation per se would have the greatest impact on newly formed nerve 
fibres. Previous studies on AD skin have demonstrated increased innervation (52, 70, 
71). Acute stress, e.g. sonic stress for 24 h (72) in mice and acute social stress for 24 
h in humans (73) also increases skin innervation. In the literature, there are disparate 
findings. For example, one human study of AD has, in agreement with our results, 
shown that the number of nerve fibres was decreased in involved compared to non-
involved eczematous skin (74). A possible explanation for the results in study I could 
be that the stress situation used was a chronic one. Initially acute stress might increase 
innervation, but it might decrease with time. Another explanation could be that there 
has been a mechanical injury of the nerve fibres, due to the higher degree of 
inflammation, and caused by the scratching. The scratching per se might be amplified 
due to central effects of the chronic stress, lowering the threshold for perception of 
pruritus, as well as the increased inflammation in the skin.  
   As mentioned earlier, the degree of inflammation was higher in the SE group 
compared to the other groups. Alternative mechanisms exists that could affect the 
innervation and formation of nerve fibres in the skin. One is the possible modulation 
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of the function of keratinocytes due to the inflammation. Keratinocytes release 
mediators such as NGF which are reported to have a trophic effect on sensory 
neurons (75).  
   The fact that there was no difference in the GAP-43 positive nerve fibre expression 
between the SE and NSE group indicates that the chronic mild stress does not seem to 
affect the newly formed nerve fibres. In rat models of chronic stress (chronic 
psychosocial and chronic restraint stress) it has been shown that stress resulted in a 
decrease of hippocampal progenitor cells, when analysing the expression of Ki-67 
protein (76), and also suppression of neurogenesis in the hippocampus, using a 
bromodeoxyuridine (BrdU) labelling method (77, 78), both methods measuring cell 
proliferation. Yet, after using chronic restraint stress, another study reported that 
GAP-43 expression was only slightly decreased in specific areas of the hippocampus 
or not decreased when analysing the total hippocampus (79).  
   Furthermore, when investigating the expression of substance P and NK-1R in skin 
of the mice, it was found that substance P positive nerve fibres were decreased in the 
SE compared to the SC group. The values for NSE were also higher, although not 
significantly. RT-PCR of the skin showed a strong tendency to an increase of NK-1R- 
mRNA in the SE compared to NSE group. These findings suggest that the effects of 
inflammation in the skin and stress could be additive, resulting in a decreased 
distribution of substance P, possibly with a following upregulation of NK-1R in skin. 
Furthermore, the increase in number of mast cells and the increased mast cell 
degranulation in the affected skin could possibly be interpreted as a non-neuronal 
compensatory mechanism to a decreased innervation and a lowered expression of 
neuronal substance P.  
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5.1.2 Brain (II) 
The study showed a decrease of substance P in the SE compared to the NSE group in 
the medial hippocampus. In the same area a decrease was also evident in the SC group, 
even though not statistically significant. This would suggest that the psychological 
stress, as compared to the physical (in form of skin inflammation) might have the most 
important effect on the expression of substance P in this region. No significant changes 
in substance P distribution were observed in amygdala or prefrontal cortex. It seems 
that there are different responses to psychological stress in the form of chronic mild 
stress and physiological stress depending on the examined areas of the nervous system. 
In the skin our results indicate an additive effect of the two different stressors resulting 
in a slight decrease of substance P and an increase of NK-1R, while results from the 
brain suggest that the area most sensitive to both stress and eczema is the hippocampus, 
where chronic stress might result in a decreased expression of substance P. A previous 
study reported an increased expression of substance P in the central amygdala after 
exposure to restraint induced stress (80). The findings presented here, showing no 
significant difference, could be related to the type of stress used, not the acute but the 
chronic mild stress.  
 
5.2 HUMAN STUDIES (III-IV) 
5.2.1 Cross sectional study (III) 
The investigation of distribution of tachykinins in skin with correlation to 
psychological traits showed an increase of substance P positive nerve fibres in lesional 
compared to non-lesional AD skin as well as a decrease in non-lesional compared to 
healthy control skin. As previously mentioned, other studies have shown alterations in 
the number of substance P fibres, and an altered substance P concentration in lesional 
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AD skin compared to control skin, see (40). Recent studies have also shown an increase 
in plasma substance P in AD patients compared to healthy individuals (61, 81-84). 
   A higher number of NKA positive fibres were noted in lesional compared to non-
lesional skin and the number of NKA positive cells were increased in lesional 
compared to both non-lesional and control skin. This finding of NKA positive cells has, 
to the best of our knowledge, not previously been reported in AD.  
   The study revealed no difference in numbers of NK-1R positive cells, this being in 
agreement with earlier studies (85, 86). However, the results reported here indicate a 
different functional activity with an increased degranulation and epidermal infiltration 
of NK-1R positive cells in lesional compared to non-lesional and control skin.  
 
Personality is connected to experience of health status and disease. It has been debated 
if, in addition to abnormal immune response, psychological factors such as stress or 
personality could play a central role in the pathogenesis of AD (87). 
   In study III the aim was to investigare the relationship between personality traits 
and the perceived outcome of AD. The hypothesis was that the study would show a 
correlation between clinical characteristics, e.g., the extent of disease (SCORAD) and 
pruritus (VAS), and psychodemographic data, like personality, anxiety or depression, 
as well as between clinical characteristics and expression of tachykinins in the skin.  
   The study could not establish any correlation between extent of disease and 
expression of tachykinins in the skin. In this context, a study by Toyoda et al. (84) 
suggested that substance P could be a useful marker in studying the activity of AD, 
since they found a correlation to SCORAD, with substance P in plasma. In addition, a 
correlation between substance P and quality of life has been reported by Hon et al. (81). 
In contrast, two other studies reported no correlation between AD severity and 
substance P in plasma (82, 83). Even though the present investigation was not able to 
  44 
confirm any correlations between tachykinergic markers and clinical characteristics, it 
should be noted that in our investigation both NKA and NK-1R positive structures were 
correlated to local inflammatory parameters such as degree of inflammatory infiltrates 
and acanthosis. 
    We determined no correlation between pruritus and any of the studied 
histopathological parameters, but did with somatic trait anxiety and stress 
susceptibility, respectively. Previous studies in humans and mice have suggested 
substance P to be an important pruritic mediator. Another study, in psoriasis, has shown 
that NK-2R positive cells and substance P positive fibres were correlated with the level 
of pruritus (88). The lack of correlation for pruritus in the present study indicates the 
complexity of pruritic signalling during skin inflammation. It is also of importance to 
consider the method by which pruritus is measured when interpreting the data. In this 
study the level of pruritus was measured at a single time point using a VAS-scale, 
grading the patient’s perceived itch during the last three days. Actual scratching was 
not determined. Different additional ways to measure pruritus have been used in other 
studies, for example by recording wrist movements (81). This study of children with 
AD showed a correlation between pruritus and plasma level of substance P, in contrast 
to subjective symptoms of pruritus. Another possible option is to use a questionnaire-
based pruritus score (83). In that study the authors could show a correlation between 
plasma levels of substance P and pruritus in AD. 
    Furthermore, the correlation analysis revealed a correlation between NK-1R positive 
cells in lesional and non-lesional skin, and depression score. This concords with 
previously published data regarding psoriasis, where it was reported a correlation 
between depression score (Beck’s Depression Inventory being used) and substance P 
and NK-1R positive cells (88). This is interesting in the context that NK-1R antagonists 
have been tested as antidepressive substances (89). The correlation indicates that 
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tachykinergic signalling pathways are of importance in AD, and that depressive 
symptoms could have an additional influence on skin immunity. 
   Finally, regarding the correlation between impulsivity and NKA positive cells in the 
present study, preclinical data from other species have earlier reported a role of the NK-
1R for impulsivity in rodents (90). 
  
5.2.2 Treatment study (IV) 
Taken together, the results from the third study, showing increase in substance P and 
NKA positive nerve fibres/ cells, indicate that neurogenic inflammation and tachykinin 
mediators are of importance in the atopic skin. To further investigate the functionality 
of tachykinins in AD, it was of interest to examine if the treatment with an NK-1R 
antagonist could be effective in AD.  
   This last study was performed to evaluate potential additive effects of aprepitant to a 
standard topical treatment. We hypothesized that aprepitant in the dose of 80 mg daily 
would contribute to a decrease of pruritus and inflammation, and thereby change the 
course of disease, even for this short time period. Aprepitant is an NK-1R antagonist, 
available in Sweden and approved for treating nausea during cancer treatment in the 
dose of 125 mg the first day and 80 mg the two following days. In a study by Ständer et 
al. from 2010 (58), pruritic skin conditions of different types were treated rather 
successfully with 80 mg daily for 1 week. We therefore chose the dose of 80 mg/day 
for seven days.  
  The results showed a significant decrease in extent of disease and pruritus in both the 
treatment and the control group. However, no additive effect of aprepitant in the dose 
administered and for the time period studied was evident. This might be due to 
pharmacokinetics and possible induction of degrading system in the liver as a possible 
explanation, especially when the interim analysis (after 31 patients) revealed a tendency 
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of a significantly lowered pruritus on Day 3. The standard dose for the approved 
indication for chemotherapy-induced nausea (the approved indication in Sweden 
today), is 150 mg the first day and 80 mg/day on the two following days. In 
consideration of this, it was of interest to determine whether the effect would be better 
during other time-points during the week. However, this sub-analysis failed to show 
any effect and we could not observe any significant changes between the groups on 
either Day 3 or Day 5 when including all patients (n=39 or 41). Considering the 
efficient effect of topical treatment alone, it might have been beneficial to even analyse 
pruritus in more detail, at an earlier time-point, at Day 1 or 2, to lower the impact of the 
topical treatment.  
   Regarding the dose of aprepitant used, it should be considered that the dose might 
have been too low to give an optimal effect. It has been suggested that for treatment of 
depression near complete receptor occupancy for the NK-1R antagonist is needed, and 
that an occupancy even up to 90% may be ineffective (91). In another study of co-
morbid alcohol dependence and posttraumatic stress disorder a dosage of 125 mg/day 
for 4 weeks was used based on PET studies reporting >90% central receptor occupancy 
at this dose (92), although, no effect could be reported. It would therefore have been 
interesting to evaluate a higher dose of 125 mg/ day. In order to achieve a quick effect 
and in concert with the protocol recommended when treating nausea, it could also have 
been of interest to start out the first day with 125 mg followed by 80 mg daily 
thereafter, in our study. 
   What could be determined by this study is the very satisfactory effect by topical 
treatment when being used regularly and correctly, resulting in a highly significant 
improvement regarding extent and pruritus in both study groups. This was interpreted 
as due to high treatment compliance during the week of study participation. The topical 
treatment used was a moderately strong steroid crème as well as a moisturizer, and this 
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resulted in a significant improvement of both the extent of the disease as well as the 
pruritus. An earlier meta-analysis of pruritus in AD has shown that topical treatment 
with steroids would result in a decrease of 34% (93).  
   Regarding depression and anxiety there was a decrease in MADRS-S in both the 
treatment and the control group and a decrease in HAD in the control group. We were 
interested in studying the effect of the treatment on these parameters as well 
considering that NK-1R antagonists have also been investigated for the treatment of 
anxiety and depression (94). The effect of other anxiolytic treatments, e.g. tandospirone 
citrate, a serotonin (5-HT) agonist, have been studied in atopic patients and suggested 
to be useful (95). Our study was, perhaps, also too short to properly investigate the 
effects on depression and anxiety. We are, however, now considering analysing a 
subgroup of patients with high values on MADRS-S to see if they might have had a 
greater effect of the treatment.  
   There was a different gender composition in the treatment compared to the control 
group, with a clearly higher proportion of men than women in the treatment group and 
vice versa. This could also have had affected the results since aprepitant might have 
different effects dependent on gender. In the study by Ständer et al. (58) a higher 
reduction of pruritus was noted in the male patients, even though no significant gender 
difference could be found and they suggested that aprepitant could be more effective in 
male patients. This would have given us enhanced effect in our study considering the 
gender distribution, with a male predominance in the treatment group, but this was still 
not observed.   
 
Taken together, the results from these studies indicate that the mechanisms involved in 
both inflammation and pruritus in AD are complex, and not entirely dependent on 
substance P as a principle mediator and communicator via NK-1R. As mentioned 
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before, some human studies have reported no correlation between plasma substance P 
levels and SCORAD (40, 81, 82), even though this might not reflect tissue levels.. 
Furthermore, animal studies have given contradictory results regarding the pruritic role 
of substance P and NK-1R. A study of treatment with aprepitant in NC/ Nga mice 
resulted in decreased IgE levels as well as a decreased density of substance P nerve 
fibres, although with no effect on clinical signs (96). 
   One recent study in mice showed no effect by aprepitant on the scratching behaviour 
(97), whereas an earlier study (55), also in mice, and using a different NK-1R 
antagonist showed that the scratching behaviour could be inhibited by a NK-1R 
antagonist.  
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6 METHODOLOGICAL CONSIDERATIONS 
 
6.1 CHRONIC MILD STRESS STUDIES (I-II) 
It should be considered that there might be important differences between species and 
that data from mouse studies might not, in all aspects, be applicable to human 
physiology. In addition, the mice being used in study II-III were females in contrast to 
the human studies III-IV, where we included both genders.  
   In the animal studies a fourth group, non-stressed control, would have been beneficial 
to fully been able to evaluate the effects of stress per se. However, we primarily aimed 
to compare stress with inflammation.  
 
6.2 IMAGE ANALYSIS (I-II) 
Regarding the method of measuring nerve fibre density in the skin of the mice, using 
image analysis, it can be discussed if it is the most optimal method. It is a relatively 
objective method and it limits the risk of bias from the observer, but it might have 
affected the results of the studies. In the inflamed skin the epidermis is hypertrophic 
and this might have affected the results, lowering the density of nerve fibres in relation 
to the area of epidermis. However, if there would be a hypertrophy of the epidermis the 
nerve fibres would presumably be longer and therefore this would maybe not influence 
the results to a great deal. Considering this, image analysis may have some limitations 
when measuring nerve fibres in the skin.  
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6.3 IMMUNOHISTOCHEMICAL METHODS (II-III) 
When staining for the distribution of receptors one has to consider if the distribution of 
the receptors reflects their physiological activity. With the method used we cannot 
determine whether the receptors are active on the surface of the cells. This would 
require other methods. A complementary method to using antibodies would be to use 
the “binding in situ”-method by using a biotinylated peptide to enable investigating 
binding specificity (85).  
   In study II we could not detect NK-1R in the investigated areas of the brain. This is in 
contrast to previously documented expression of NK-1R using different techniques, 
including immunohistochemistry (94). However, we did find NK-1R-immunoreactive 
nerve fibres in other parts of the brain, and the PCR results also showed a positive 
signal. Nakaya et al. (98) used an Avidin Biotin Complex staining method, which might 
have provided higher sensitivity compared to our method. Another possibility is that 
the stress and/or inflammation might have caused a downregulation of the NK-1R gene, 
as has been reported previously in rat models of pain and stress (99). This is, however, 
unlikely. 
 
6.4 TREATMENT STUDY (IV) 
The treatment study has given rise to further questions. First of all, it can be discussed 
if the control group was the most optimal. At first we would have liked to have ensured 
a more even gender distribution in the two groups, but difficulties recruiting patients 
made us drop the stratified randomisation. When considering the dose given, a higher 
dose (125 mg/day) could maybe, as discussed earlier, have given a more optimal effect. 
To further investigate this it would have been possible to have two different treatment 
groups with two different doses. However, due to limited resources we chose the dose 
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of 80 mg/day as was described in the study by Ständer et al.(58). For a possible positive 
treatment effect we would still have had the problem of excluding a placebo effect, 
since the study was an open randomized trial.  
   As discussed earlier there are different ways of measuring pruritus. The method we 
used was an attempt to get an additional tool to evaluate the effect of pruritus. However 
the method proved to be difficult to standardize and the results showed large variations.  
   It shall also be noted that the basal treatment that we used in the study might be so 
potent that the effects of the systemic treatment were not separately detectable.  
Considering the time it may take to gain the effect of steroids topically it might be of 
interest to already analyse the effect at Day 1-2.  
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7 CONCLUSIONS 
 
Chronic mild stress might cause a decrease in preformed cutaneous nerves in 
eczematous skin in NC/Nga mice. The slowdown of the process of neuronal 
regeneration in the eczematous skin of atopic mice could be due to the inflammation 
per se. 
   Furthermore, the combination of chronic mild stress and eczema may result in 
alterations in substance P expression in the skin and brain. Symptoms of depression and 
diseases of chronic inflammation in barrier tissues may reflect a common underlying 
pathophysiology involving substance P as a central mediator. This may be of interest 
for future pharmacological treatment of AD and the worsening of AD during chronic 
stress, targeting substance P pathways. 
   In humans substance P and NKA are likely to have a role in the inflamed skin of AD. 
In addition, there was a relation between NK-1R positive cells and depression score. 
This indicates that tachykinergic signalling pathways are of importance in AD, and that 
depressive symptoms could have an additional influence on skin immunity. 
   However, when interfering with substance P pathways by blocking the NK-1R with 
aprepitant, we have not been able to detect an additive effect by this treatment 
compared to a standardized topical treatment in AD patients. Nevertheless, the clinical 
trial setting supported the patients to be compliant to all study procedures and resulted 
in significant relief of the disease symptoms in both study groups. 
   In conclusion, my studies suggest that tachykinins seem to have a role in 
pathogenesis of AD, even though the underlying mechanisms are complex and not fully 
understood. 
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8 FUTURE PERSPECTIVES 
 
It is still of interest to further investigate the effects of blocking NK-1R with aprepitant. 
As discussed above, it would be of interest to primarily investigate a higher dose to see 
if it would be more efficient. It would, even if it probably would result in more 
difficulties in recruiting patients, be of interest to investigate the treatment with 
aprepitant alone compared to placebo. This would, however, have to be preceded by a 
couple of weeks of wash-out from the patients’ standard topical treatment, which is in 
my opinion difficult to motivate the patients to do, and might result in even more 
recruitment difficulties.  
   There are other inflammatory skin conditions that would be of interest to treat with 
aprepitant, for example prurigo nodularis, where the pruritus is even worse and where 
neuropeptides and neurogenic inflammation are considered to have a role in the 
pathogenesis. Ständer et al. (58) reported promising results treating different 
inflammatory skin diseases with aprepitant, and it would be interesting to see if the 
results are reproducible in another setting. 
   There are other peptides, like CGRP and gastrin releasing peptide (GRP) that have 
been suggested to be involved in itch in AD, and which are related to inflammation 
(100) and itch, respectively (101). It would be of interest to further investigate the 
distribution of these peptides in the skin of AD. There is a new CGRP antagonist 
developed for the treatment of migraine (102), which would be interesting to examine 
in relation to AD. There have been a few studies investigating intradermal injection and 
topical administration of CGRP-antagonists in contact dermatitis, resulting in an 
inhibition of reaction to nickel in patients allergic to nickel (103) and vasoconstriction 
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(104), respectively.  
   Regarding the neurocutaneus perspective it is of interest to further investigare how 
stress and depression influence different inflammatory skin conditions, and vice versa. 
Since pruritus is a central symptom in many inflammatory skin diseases and is also 
regulated at a central level this is a symptom that is of high interest. One could for 
example evaluate the benefit of additional treatment of skin diseases, especially if you 
can establish stress and depression as a contributing factor for the patient, with anti-
depressive agents and/or psychotherapy such as cognitive behavioural therapy (CBT).  
   It is also of importance to find new forms to collaborate between the university 
hospitals and private actors. It is, and is going to be an even greater challenge to get the 
patients in contact with the researchers. We will have to find ways, reach out to the 
private sector and make it profitable to take part in research and also to create platforms 
for the patients to more easily get in contact with the researchers.  
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9 SAMMANFATTNING PÅ SVENSKA 
Atopisk dermatit (AD) är en vanlig, till viss del ärftlig, kronisk hudsjukdom vilken ofta 
uppkommer i tidig barndom (15-20% av barn i Sverige drabbas). Av vuxna har 2-3% 
kvarstående besvär. Patogenesen involverar bland annat en ändring i distributionen av 
neuropeptider, däribland substans P. Denna neuropeptid spelar också en viktig roll vid 
stress och det är välkänt att stress kan ge upphov till försämring av AD. 
   Målsättningen var att utreda vilken roll substans P och andra tachykininer spelar i 
utvecklingen av AD, klåda och stressförsämring.  
   Initialt användes en djurmodell för att studera substans P och dess receptor NK-1R i 
relation till eksem och stress. Kombinationen av stress och eksem resulterade i en 
minskning av nervfibrer i huden och själva inflammationen i den eksemdrabbade huden 
tycks ha haft mest negativ effekt på de nybildade nervfibrerna. Även uttrycket av 
substans P och NK-1R förändrades i både huden och hjärnan. 
    Därefter studerades AD hos patienter och då korrelerades uttrycket av substans P och 
NK-1R i huden till grad av eksemutbredning, klåda samt patienternas oros- och 
depressionsnivå. Resultaten visade en ökning av substans P-och NKA-positiva 
nervfibrer samt NKA-positiva celler i eksemdrabbad hud. Vidare kunde det fastställas 
en korrelation mellan NK-1R-positiva celler i huden och grad av inflammation i huden. 
NK-1R positiva celler korrelerade även till patienternas grad av depression.   
   Slutligen genomfördes en öppen randomiserad klinisk prövning där effekten av en 
NK-1R-antagonist, aprepitant, på utbredningen av eksemet och klådan hos patienter 
med måttlig/svår AD utvärderades. Ingen additativ effekt av behandlingen med 
aprepitant jämfört med endast lokalbehandling kunde fastställas. Däremot visade 
studien på en signifikant förbättring i båda grupperna, något som talar för att god 
följsamhet ger god behandlingseffekt vid behandling med lokala steroider.  
   Sammanfattningsvis talar studierna för att tachykininer tycks spela en roll i 
patogenesen och stressförsämringen av AD. Samspelet är dock komplext och det 
behövs vidare undersökningar för att vidare utreda de exakta mekanismerna. 
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